JNJ Chart

1 Month

	Date	Diff
	2025-05-05	-0.72 %
Johnson & Johnson (JNJ) stock fell by 0.72% likely due to market reactions to the recent FDA approval of Teva Pharmaceuticals’ interchangeable biosimilar SELARSDI, which could increase competition for JNJ's Stelara, impacting its market share and revenue. Johnson & Johnson (JNJ) stock declined by 0.72% following an analysis of its performance compared to other stocks discussed by Jim Cramer on "Mad Money." The decline may be attributed to market reactions to Cramer's commentary and overall investor sentiment towards the stock. Johnson & Johnson's (JNJ) stock experienced a decline of 0.72% due to increasing competition in the biosimilars market following the FDA approval of SELARSDI™, a new interchangeable biosimilar that could potentially affect JNJ's market share of Stelara®, its reference biologic product. The Johnson & Johnson (JNJ) stock declined by -0.72% potentially due to market reactions to the announcement of a clinical trial collaboration with ORIC Pharmaceuticals, which may have shifted investor focus or raised concerns about competition in the oncology space. Johnson & Johnson's stock (JNJ) declined by 0.72% following the FDA's approval of Selarsdi, a competing product from Teva and Alvotech, which is now considered interchangeable with JNJ's Stelara, potentially impacting JNJ's market share.
	2025-05-01	-1.18 %
Johnson & Johnson (JNJ) stock declined by 1.18% amid concerns over the impact of President Trump's tariffs on the U.S. economy, which recently reported a GDP shrinkage, leading to fears of recession and contributing to market volatility. The article discusses a decline in Johnson & Johnson (JNJ) stock, which fell by 1.18% following President Trump's assertions about tariffs potentially leading to higher prices and fewer products in the U.S., amid concerns about the economy shrinking and the potential impacts on consumer prices stemming from his trade policies. The decline can be attributed to market uncertainties related to Trump's trade policies and their ramifications on the economy, which has caused investor nervousness despite Trump's efforts to promote corporate investments in the U.S. Johnson & Johnson (JNJ) stock fell by 1.18% due to concerns over a $400 million financial impact related to tariffs mentioned by the company. Johnson & Johnson (JNJ) stock declined by 1.18% amid concerns about the impact of President Trump's tariffs and a recent report revealing a contraction in the U.S. economy, which has caused investor nervousness and heightened fears of a potential recession. Johnson & Johnson (JNJ) stock was down 1.18% due to ongoing market volatility and concerns related to the escalating trade war between the U.S. and China, which are leading investors to seek safer assets.
	2025-04-30	+0.26 %
The article discusses the rising stock price of Johnson & Johnson (JNJ), noting it was up by 0.26% last night, potentially reflecting positive market sentiment or investor confidence. However, it does not provide specific reasons for the stock's increase. Johnson & Johnson (JNJ) stock rose by 0.26%, possibly due to positive market sentiment or company-specific developments, although the article does not provide specific reasons for the increase. Johnson & Johnson (JNJ) stock was up 0.26% amidst President Trump's acknowledgment that his tariffs might lead to higher prices and fewer products in the U.S., while he emphasized that China would suffer more from the ongoing trade war, suggesting potential corporate investment growth in the U.S. as a result. The increase in JNJ stock may be attributed to the optimism around new corporate investments in the U.S. as highlighted by Trump, despite concerns over potential economic impacts from tariffs.
	2025-04-29	+0.36 %
Johnson & Johnson (JNJ) stock experienced a 0.36% increase, likely driven by high trading volume and overall strong performance in the healthcare sector, as indicated by its position among the top stocks to watch. Johnson & Johnson (JNJ) stock rose by 0.36% due to the company's successful integration of artificial intelligence (AI) to automate internal processes and enhance productivity, demonstrated by their CIO Jim Swanson's insights during the Responsible AI in Global Business Conference and their commitment to upskilling employees in AI adoption.
	2025-04-28	+0.5 %
The article discusses Johnson & Johnson's (JNJ) recent stock performance, noting a 0.5% increase, attributed to strong operational sales growth of 4.2% across its business segments, strategic investments in R&D, and a history of consistent profitability and dividend growth, positioning it favorably against recession fears and market volatility.
	2025-04-25	-0.23 %
Johnson & Johnson (JNJ) stock fell by 0.23% despite receiving a "Moderate Buy" recommendation from analysts, with some recent price target reductions likely contributing to the decline. Johnson & Johnson (JNJ) stock decreased by 0.23% due to various factors typically affecting pharmaceutical stocks, such as market demand fluctuations and possibly specific developments in clinical trials or regulatory approvals impacting the sector.
	2025-04-24	-0.29 %
Johnson & Johnson (JNJ) stock fell by 0.29% amid broader market sentiment, which reflects recent declines in the stock market discouraging companies from pursuing acquisitions or takeovers. Johnson & Johnson (JNJ) stock fell by 0.29% last night, trading down to $156.65 amid broader volatility in the pharmaceutical sector influenced by factors like clinical trials and regulatory news. Johnson & Johnson (JNJ) stock decreased by 0.29% due to a challenging market environment marked by geopolitical instability, economic uncertainty, and unresolved inflation pressures that have impacted investor confidence across various sectors.
	2025-04-23	-1.5 %
Johnson & Johnson (JNJ) stock decreased by 1.5% amid broader concerns over economic conditions and corporate investments promised during Trump's presidency, with investors likely reacting to uncertainty rather than the company's specific fundamentals. The decline in JNJ's stock could be attributed to market reactions to broader economic signals and uncertainties, rather than any direct issues with the company itself. The Johnson & Johnson (JNJ) stock was down 1.5% due to broader concerns in the corporate sector about the negative impacts of President Trump's tariff policies, which have created uncertainty and reduced consumer confidence in the economy.
	2025-04-22	+0.53 %
Johnson & Johnson (JNJ) stock experienced a 0.53% increase, likely due to its strong brand reputation and the affordability of its budget-friendly first aid kits, which enhance consumer trust and demand for its health products.
	2025-04-21	-0.35 %
Johnson & Johnson (JNJ) stock was down by 0.35% due to fluctuations in the pharmaceutical market, influenced by trading volumes and performance of related companies like Eli Lilly and Novo Nordisk. Johnson & Johnson (JNJ) stock declined by 0.35% amid a week where several companies announced dividend increases, likely reflecting broader market trends or company-specific factors unrelated to its long-standing dividend growth. The reason for the decline may be related to market fluctuations, investor sentiment, or external economic factors, rather than a direct correlation with its recent dividend increase. Johnson & Johnson's stock (JNJ) experienced a 0.35% decline last night, attributed to overall market fluctuations affecting investor sentiment and trading volume around dividend stocks. The article discusses Johnson & Johnson's (JNJ) stock performance and highlights that it fell by 0.35%, potentially due to concerns affecting dividend-paying stocks and competitive analysis against other top dividend stocks. Johnson & Johnson (JNJ) stock experienced a decline of 0.35% due to its general performance reflecting market trends affecting healthcare stocks, including fluctuations in trading volumes and investor sentiment within the sector.
	2025-04-17	+2.31 %
Johnson & Johnson (JNJ) stock increased by 2.31% due to positive investor sentiment towards pharmaceutical companies amid significant trading volumes, highlighting market anticipation of advancements in medical research and product developments. Johnson & Johnson's stock rose 2.31% following the release of its Q1 earnings, which surpassed analyst expectations for both revenue and earnings, primarily driven by strong sales of key drugs despite a decline in Stelara sales. Johnson & Johnson's stock (JNJ) increased by 2.31% due to strong trading volume and investor confidence in the pharmaceutical sector, which is buoyed by advancements in medical research and product development.
	2025-04-16	+0.19 %
Johnson & Johnson's stock (JNJ) increased by 0.19%, reaching $153.73, likely driven by market interest in pharmaceutical stocks due to innovation and demand in the healthcare sector, as highlighted by a focus on the trading activity and volume among leading companies in the industry like Eli Lilly and Pfizer. Johnson & Johnson (JNJ) stock rose by 0.19% due to its strong financial performance, highlighted by a 5.2% increase in quarterly revenue, the announcement of a 4.8% dividend increase, and its status as a distinguished Dividend Monarch, despite ongoing legal challenges. Johnson & Johnson (JNJ) stock rose by 0.19% last night, driven by positive sentiment from the company's management downplaying the potential impact of President Trump's planned tariffs on pharmaceuticals and emphasizing their commitment to U.S. manufacturing. Johnson & Johnson (JNJ) stock went up by 0.19% due to positive market sentiment potentially driven by advancements in biopharmaceutical collaborations and technological innovations in drug development, as indicated by the recent merger announcement between Salarius Pharmaceuticals and Decoy Therapeutics, which includes notable scientific expertise that may influence the broader sector positively. Johnson & Johnson (NYSE:JNJ) shares experienced a slight increase of 0.19% despite a recent downgrade in price target from Raymond James and mixed analyst ratings, largely attributed to the company's strong quarterly earnings report that exceeded expectations. The stock's rise can be attributed to better-than-expected earnings results, which improved investor confidence in the company's financial performance despite analysts adjusting their price targets.
	2025-04-15	-0.48 %
Johnson & Johnson (JNJ) stock recently experienced a decline of 0.48%, attributed to the general volatility of pharmaceutical stocks due to sensitivity to regulatory changes, drug approvals, and market demand fluctuations. Johnson & Johnson stock declined by -0.48% as it fell in line with the broader market, despite exceeding first-quarter expectations and raising its 2025 sales projections, likely due to external market pressures such as tariff headwinds. Johnson & Johnson (JNJ) stock declined by 0.48% despite beating first quarter earnings expectations, primarily due to concerns about the impact of tariffs on its medical device business and ongoing legal issues related to talc litigation. Johnson & Johnson (JNJ) stock declined by 0.48% due to concerns over potential US tariffs on the pharmaceutical industry, which could disrupt supply chains and lead to medicine shortages, despite a strong quarterly performance and maintained earnings forecast. Johnson & Johnson's stock decreased by 0.48% due to a decline in the broader market, even though the company exceeded first-quarter earnings expectations and raised its sales forecast for 2025.
	2025-04-14	+1.73 %
Johnson & Johnson (JNJ) stock rose by 1.73% due to its strong positioning among top dividend-paying stocks, attracting investor interest. Johnson & Johnson (JNJ) stock rose 1.73% due to positive sentiment surrounding the upcoming earnings reports amidst an overall bullish outlook on equities, despite heightened market uncertainty related to tariff policies.
	2025-04-11	+2.04 %
Johnson & Johnson (JNJ) stock rose 2.04% due to anticipation of positive updates from the company regarding ongoing litigation and potential news about a new drug release, as the pharmaceutical industry adapts to changing federal policies. Johnson & Johnson (JNJ) stock rose 2.04% due to positive expectations surrounding its upcoming earnings announcement, driven by anticipated sales growth in key drugs and a strong MedTech segment, despite challenges like declining Stelara sales from biosimilar competition. Johnson & Johnson (JNJ) stock rose by 2.04% last night, potentially due to positive market sentiment or investor confidence amidst broader economic conditions. The increase in JNJ stock could be attributed to favorable earnings expectations or improvements in market conditions that enhance investor confidence in the company.
	2025-04-10	-1.51 %
Johnson & Johnson (JNJ) stock declined by -1.51% due to market fluctuations, as highlighted in the article which focuses on the comparisons between small-cap medical companies Windtree Therapeutics and Tevogen Bio, but does not provide specific reasons for JNJ's stock decrease. Johnson & Johnson (JNJ) stock declined by 1.51% amid a volatile market influenced by President Trump's tariff policies, specifically the increased tariffs on Chinese imports, which raised concerns among investors about heightened costs and economic uncertainty for companies reliant on global trade. Johnson & Johnson (JNJ) stock fell by 1.51% to $148.90, attributed to its relatively high trading volume and the overall performance trends in the healthcare sector, as well as potential market reactions to economic indicators and earnings outlooks impacting investor sentiment.
	2025-04-09	+0.65 %
The article discusses a surge in stock markets following President Donald Trump's decision to pause tariffs against most nations while increasing tariffs on China, which positively impacted stocks like Johnson & Johnson (JNJ), resulting in a 0.65% increase. Johnson & Johnson's stock likely rose due to the overall market rally spurred by reduced tariff fears in the US and a favorable trading environment for companies outside of China, which can lead to improved investor confidence and performance expectations. Johnson & Johnson (JNJ) stock increased by 0.65% despite overall market volatility and negative sentiment towards pharmaceutical companies due to tariff threats, likely benefiting from investors seeking safety in stable healthcare stocks amid broader market uncertainty. Johnson & Johnson (JNJ) stock rose by 0.65% following Representative Gilbert Ray Cisneros, Jr.’s recent purchase of shares, which indicates investor confidence and potential positive sentiment in the company's future performance amidst favorable stock ratings and strong earnings reports. Johnson & Johnson (JNJ) stock rose by 0.65% likely due to its successful lobbying for tariff exemptions during ongoing trade tensions, which may create a more favorable operational environment for the company compared to other industries adversely affected by these tariffs. Johnson & Johnson (JNJ) stock saw a 0.65% increase due to strong interest and trading activity among pharmaceutical stocks, which are influenced by various market factors such as clinical trial results and healthcare policy shifts.
	2025-04-08	-0.41 %
Johnson & Johnson (JNJ) stock decreased by 0.41% or $6.79, reaching $153.03 due to high trading volume and the overall volatility in the healthcare sector, which can be influenced by market fluctuations and investor sentiment. Johnson & Johnson (JNJ) stock fell by 0.41% to $153.03, influenced by various market factors typical in the healthcare sector, such as trading volume fluctuations and broader market conditions affecting investor sentiment. Johnson & Johnson (JNJ) stock fell by 0.41%, trading down $6.79 to reach $153.03, likely driven by broader market trends affecting healthcare stocks, along with fluctuations in trading volume and investor sentiment.
	2025-04-07	-1.71 %
Johnson & Johnson (JNJ) stock experienced a decline of 1.71%, trading down $6.79 to $153.03, likely due to broader market trends affecting investor sentiment and fluctuations in stock trading volumes among major dividend-paying companies. Johnson & Johnson's (JNJ) stock declined by 1.71% to $153.03 amid heavier trading volume than usual, likely influenced by broader market factors affecting pharmaceutical stocks, including investor sentiment and overall market dynamics. Johnson & Johnson (JNJ) stock fell by 1.71% following President Trump's announcement of tariffs that could raise costs for American companies and consumers, potentially impacting the overall market and investor sentiment. Johnson & Johnson (JNJ) stock declined by -1.71% due to broader market trends affecting investor sentiment and possibly investor caution ahead of its anticipated dividend increase, which is expected to be smaller than previous raises.
	2025-04-04	-4.12 %
Johnson & Johnson (JNJ) stock fell by 4.12% last night, attributed to lower trading volumes and possible investor concerns about the company’s recent performance despite its healthy market position and product offerings in the healthcare sector. The article discusses how Johnson & Johnson's stock, along with other Swedish companies, has dropped by 4.12% due to the impact of President Donald Trump's tariffs on imports, which has raised concerns about potential economic slowdown and retaliatory measures. The decline in JNJ's stock is primarily attributed to the broad market reaction to the tariffs and fears of a global recession. Johnson & Johnson's stock (JNJ) declined by 4.12% likely due to downgrades in price targets by several analysts, with Morgan Stanley lowering theirs significantly, which may have influenced investor sentiment negatively. Johnson & Johnson's stock (JNJ) fell by 4.12% following a series of mixed ratings and price target adjustments from various analysts, despite reporting earnings that beat consensus estimates.
	2025-04-03	+2.87 %
The article discusses a bullish outlook on Flex Ltd. (FLEX), highlighting its strong cash flow, efficient operations, and market positioning despite recent stock declines, which may suggest underlying potential value despite a decline in revenues. Regarding Johnson & Johnson (JNJ), the article does not explicitly explain why its stock increased by 2.87%; however, stock prices generally rise due to positive market sentiment, strong earnings reports, favorable news, or investor confidence in the company's stability and growth prospects.
	2025-04-02	+1.38 %
Johnson & Johnson's stock rose 1.38% after previously experiencing a decline due to unsuccessful settlement efforts regarding liability cases related to its baby powder and talc products, indicating potential recovery or investor optimism despite recent legal challenges. Johnson & Johnson (JNJ) stock rose 1.38% despite a broader market decline driven by uncertainty over potential tariffs, likely due to investor optimism following previous volatility and recent overall market fluctuations. The rise in JNJ's stock could be attributed to investors seeking potential opportunities as market reactions to economic news have created buying pressure amid the uncertainty, contrasting with the negative sentiment affecting other sectors. Johnson & Johnson (JNJ) stock rose 1.38% despite a previous 7% drop following a legal setback, as analysts see the stock as an attractive buying opportunity at its current price of approximately $155 due to its strong operating performance, moderate valuation, and resilience compared to the broader market. The increase in JNJ stock may be attributed to positive investor sentiment regarding its favorable valuation and performance metrics despite ongoing litigation risks.
	2025-04-01	-7.59 %
Johnson & Johnson's (JNJ) stock fell by -7.59% due to concerns over the potential impact of new tariffs proposed by the Trump administration on the pharmaceutical sector, which could lead to significant commercial challenges for companies operating in Ireland and affect their investment decisions in the long term. Johnson & Johnson (JNJ) stock fell by 7.59% following a U.S. bankruptcy judge's rejection of the company's $10 billion proposal to resolve numerous lawsuits claiming that its talc products, including baby powder, caused ovarian cancer. Johnson & Johnson (JNJ) stock dropped 7.59% after a judge rejected the company's proposed bankruptcy plan aimed at settling thousands of claims linked to its talc products allegedly causing ovarian cancer. Johnson & Johnson's stock fell by 7.59% after a judge rejected the company's $10 billion proposal to settle numerous lawsuits related to talc products. Johnson & Johnson's stock fell nearly 5% due to a federal judge denying its settlement plan related to baby powder containing talc.
	2025-03-28	+0.36 %
Johnson & Johnson's (JNJ) stock rose by 0.36% possibly due to positive developments in their partnered clinical trials, particularly the collaboration with LAVA Therapeutics on innovative cancer treatments that may enhance shareholder value in the biopharmaceutical sector. Johnson & Johnson (JNJ) stock increased by 0.36% amidst a projected growth in the global antiseptic products market, which is driven by heightened hygiene awareness post-pandemic, the rising prevalence of chronic diseases, and expanding applications in healthcare and consumer use.
	2025-03-27	+0.87 %
Johnson & Johnson (JNJ) stock rose by 0.87% likely due to positive market sentiments surrounding the pharmaceutical sector, amidst strong trading volumes and continued interest in healthcare innovations and developments.
	2025-03-26	+0.43 %
Johnson & Johnson (JNJ) stock rose by 0.43% largely due to positive financial results and growth milestones announced by Alvotech, a biotech company specializing in biosimilars, indicating strong performance and future potential in the biotechnology sector that JNJ is associated with. Johnson & Johnson's (JNJ) stock rose by 0.43% due to positive financial results and significant developments in Alvotech, a biotechnology company that reported record product sales and milestones, indicating strong growth potential in the biosimilar market, which could have positive implications for JNJ's affiliates or competitors in that space. Johnson & Johnson's stock (JNJ) rose by 0.43% following the announcement of Band-Aid's new collection featuring iconic artworks, which indicates a strategic shift towards targeting adult consumers and transforming bandages into fashion accessories. The stock likely went up due to positive market reception of this innovative consumer product strategy, reflecting the company's ability to adapt and attract a broader customer base.
	2025-03-25	-1.39 %
Johnson & Johnson (JNJ) stock fell by 1.39% partly due to investor concerns over increasing government regulation in the healthcare sector, as discussions around controlling drug prices and limiting pharmaceutical companies' profits could negatively impact their future earnings.
	2025-03-24	-0.21 %
Johnson & Johnson (JNJ) stock was down by 0.21% last night, but the article does not specify the exact reasons for this decline. Potential factors could include market trends, investor sentiment, or company-specific news, but these details are not provided in the summary. Johnson & Johnson (JNJ) stock declined by 0.21% due to investor concerns regarding ongoing developments in its subsidiary partnerships and the merger activities of Salarius Pharmaceuticals with Decoy Therapeutics, which may influence the market's perception of JNJ's future prospects in the biopharmaceutical sector. Johnson & Johnson (JNJ) stock was down by -0.21%, likely due to market reactions that may encompass broader factors affecting the healthcare sector, regulatory uncertainties, or potential impacts from developments in related companies like OncoCyte Corporation, which recently made advancements in their transplant rejection diagnostics that could shift competitive dynamics in the industry. Johnson & Johnson (JNJ) stock was down 0.21% due to fluctuations in market performance among healthcare stocks and broader industry trends affecting investor sentiment.
	2025-03-21	+0.37 %
Johnson & Johnson (JNJ) stock increased by 0.37% following recent announcements of significant U.S. investments, including the groundbreaking of a high-tech facility in North Carolina, which promise to create jobs and bolster manufacturing in the U.S. economy.
	2025-03-20	+0.02 %
The article discusses the recent 0.02% increase in Johnson & Johnson (JNJ) stock attributed to positive developments from Oxford Metrics, including the appointment of Dr. Simon Gunter as managing director of their smart manufacturing division and the securing of three contracts related to contact lens inspection systems, indicating growth and strong demand for their technology. Johnson & Johnson (JNJ) stock experienced a slight increase of 0.02% last night, reflecting positive market sentiment which could be attributed to renewed investor confidence and a stable performance in its healthcare offerings. Johnson & Johnson (JNJ) stock rose by 0.02% due to optimistic market prospects in the oncology small molecule drugs sector, which indicates growth opportunities and strategic investments in cancer treatment innovations.
	2025-03-19	-0.77 %
Johnson & Johnson (JNJ) stock fell by 0.77% due to market fluctuations and possible investor concerns reflected in broader market trends. Johnson & Johnson (JNJ) stock decreased by 0.77% due to various market forces affecting the pharmaceutical sector, including potential regulatory changes, patent expirations, and shifts in investor sentiment towards the broader healthcare market.
	2025-03-18	+0.87 %
Johnson & Johnson (JNJ) stock rose 0.87% last night, reflecting positive investor sentiment likely driven by the company's strong market position and ongoing developments in its pharmaceutical and medical device segments.
	2025-03-17	+0.02 %
Johnson & Johnson (JNJ) stock was up 0.02% last night, likely due to its inclusion in defensive exchange-traded funds (ETFs) like the BetaShares Global Healthcare ETF, which is attracting investors looking for stability amidst broader market volatility.
	2025-03-13	+0.09 %
Johnson & Johnson's (JNJ) stock rose by 0.09% as it is perceived to be a strong performer in a potential stagflation scenario, benefiting from its steady cash flows and diversified product portfolio in a weakening economic environment.
	2025-03-12	-1.81 %
The article does not directly address the reasons for Johnson & Johnson (JNJ) stock's decline of -1.81%. However, given that it focuses on Bavarian Nordic's upcoming annual meeting and board proposals, it may suggest a broader context involving market reactions to upcoming corporate governance changes or trends in the pharmaceutical industry which might affect investor sentiment regarding JNJ. Johnson & Johnson (JNJ) stock fell by 1.81%, likely due to the challenging landscape in the orthopedic robotic-assisted surgery market, which is hindered by high system costs despite technological advancements and growing demand for minimally invasive procedures.
	2025-03-11	-1.1 %
Johnson & Johnson (JNJ) stock fell by 1.1% likely due to negative market sentiment and mixed performance from related sectors, as implied by surrounding market activities, including stock trades by key figures such as Representative Jefferson Shreve. Johnson & Johnson (JNJ) stock dropped by 1.1%, attributed to recent analyst downgrades and lowered price targets amidst changing market sentiments despite a positive earnings report. Johnson & Johnson (JNJ) stock fell by 1.1% as Guggenheim reiterated a neutral rating and other analysts adjusted their target prices downward, contributing to investor concern and market fluctuations.
	2025-03-07	+0.52 %
The article discusses recent news related to Johnson & Johnson (JNJ) and other pharmaceutical companies, noting that JNJ's stock rose by 0.52%. The increase in JNJ's stock can be attributed to optimism around the company's future prospects amid widespread changes and developments in the pharmaceutical sector, including competitive advancements and market dynamics. Johnson & Johnson (JNJ) stock increased by 0.52% due to an upgrade of its target price by Bank of America from $159.00 to $171.00, suggesting potential for further upside, along with generally favorable analyst ratings and strong earnings performance. Johnson & Johnson (JNJ) stock rose by 0.52% likely due to the overall positive sentiment in the pharmaceutical sector, highlighted by significant trading volumes and market attention on key pharmaceutical companies including JNJ. Johnson & Johnson (JNJ) stock has risen 0.52% last night and is up 15% this year, outperforming the S&P 500, primarily due to its status as a defensive investment during market volatility, concerns over Trump's tariff policies, and its strong financial performance highlighted by attractive profit margins and a solid balance sheet.
	2025-03-06	+0.43 %
Johnson & Johnson (JNJ) stock rose 0.43% due to a combination of favorable analyst upgrades and solid earnings performance reported last month, which included beating revenue and earnings per share estimates. Johnson & Johnson (JNJ) stock was up 0.43% as part of a broader trend in pharmaceutical stocks, which tend to experience fluctuations due to factors like regulatory decisions and market dynamics. The increase in JNJ's stock value could be attributed to its operational performance and investor interest in the pharmaceutical sector amidst ongoing market activity.
	2025-03-05	-0.18 %
Johnson & Johnson (JNJ) stock experienced a slight decline of -0.18%, possibly due to investors reacting to broader market conditions or concerns over performance, rather than any specific events concerning the company itself, as the article primarily discusses Clearside Biomedical and its stock activity. Johnson & Johnson (JNJ) stock declined by 0.18% amid growing competition and advancements in gene therapy demonstrated by MeiraGTx, a company that recently showed promising results in restoring sight to children with a genetic disorder, highlighting shifts in the biotech landscape that may affect JNJ's market position. Johnson & Johnson (JNJ) stock experienced a slight decline of -0.18%, likely influenced by investor concerns stemming from broader health sector issues and ongoing litigation related to its talc-based products and Covid vaccine, reflecting uncertainties in the company's market performance.
	2025-03-04	-1.11 %
Johnson & Johnson (JNJ) stock fell by 1.11% amid a broader context of fluctuations in the medical stock sector, possibly influenced by recent shifts in investor sentiment and trading patterns.
	2025-02-26	-1.81 %
Johnson & Johnson (JNJ) stock declined by 1.81% due to negative investor sentiment, potentially influenced by broader market conditions impacting healthcare stocks and competitors. Johnson & Johnson's (JNJ) stock fell by 1.81% amid ongoing congressional hearings that scrutinized pharmaceutical benefit managers (PBMs) for contributing to high drug prices, which has raised concerns about the accountability and practices of both PBMs and pharmaceutical companies.
	2025-02-25	+1.44 %
Johnson & Johnson (JNJ) stock rose by 1.44% recently, attributed to increased trading volume and positive market momentum among major pharmaceutical companies as investors show heightened interest in the sector. Johnson & Johnson (JNJ) stock rose by 1.44% last night, likely due to positive market sentiment surrounding high-quality companies included in investment funds, such as the Betashares Global Quality Leaders ETF, which features JNJ among its top holdings. Johnson & Johnson's stock rose by 1.44%, closing at $162.35 due to significant trading activity, with 12,540,171 shares exchanged, well above its average volume, indicating increased investor interest in the company amid broader market trends in the healthcare sector.
	2025-02-21	+1.64 %
Johnson & Johnson (JNJ) stock rose by 1.64% last night, likely due to positive momentum stemming from Intra-Cellular Therapies' strong financial results and the FDA's acceptance of its supplemental New Drug Application for CAPLYTA, which could indicate promising developments in the pharmaceutical pipeline that could benefit Johnson & Johnson's interests.
	2025-02-20	+1.13 %
Johnson & Johnson (JNJ) stock rose by 1.13% following a recent influx of institutional investments and strong quarterly earnings that surpassed expectations, alongside an attractive dividend announcement. Johnson & Johnson (JNJ) stock rose by 1.13% amid mixed institutional investment activity and positive earnings results that exceeded analysts' expectations, while analysts generally maintain a "Moderate Buy" consensus rating for the stock. Johnson & Johnson (JNJ) stock increased by 1.13% last night, primarily driven by significant investments from institutional investors and positive earnings performance, which reinforced confidence in the company's prospects. Johnson & Johnson (JNJ) stock rose by 1.13% likely due to positive quarterly earnings results that exceeded analyst expectations, along with ongoing interest and investment activity from institutional investors. Johnson & Johnson (JNJ) stock rose by 1.13% following a fourth-quarter earnings report that exceeded expectations, along with increased institutional investment in the company, reflecting strong investor confidence and robust financial performance.
	2025-02-19	+1.87 %
Johnson & Johnson (JNJ) stock rose by 1.87% due to positive earnings results exceeding analyst expectations, consistent institutional investor activity, and favorable ratings from brokerages, despite a recent decrease in a stake by Empire Life Investments. Johnson & Johnson (JNJ) stock rose by 1.87% due to positive quarterly earnings that exceeded expectations and overall strong institutional investor activity, despite a lowered stake by Covenant Asset Management. Johnson & Johnson's stock (NYSE: JNJ) rose by 1.87% following a mix of institutional investor activity and positive quarterly earnings results, which included a report of $2.04 EPS that surpassed analyst estimates. Johnson & Johnson (NYSE: JNJ) stock rose 1.87% due to increased institutional investor activity, including significant purchases by hedge funds, along with a positive quarterly earnings report exceeding analysts' expectations. Johnson & Johnson (JNJ) stock rose 1.87% as institutional investors, including PineStone Asset Management Inc., increased their holdings in the company, indicating strong confidence in its performance and growth potential.
	2025-02-18	+0.05 %
Johnson & Johnson (JNJ) stock experienced a slight increase of 0.05% due to heightened institutional investment interest, with multiple hedge funds increasing their holdings in the company, suggesting confidence in its future performance despite some analysts lowering price targets. Johnson & Johnson (JNJ) stock rose by 0.05% as it saw a mix of institutional investors adjusting their stakes, positive earnings results exceeding expectations, and an upcoming dividend payment, contributing to increased investor confidence. Johnson & Johnson (JNJ) stock saw a minor increase of 0.05% last night, likely due to its status as a well-performing dividend aristocrat, which tends to attract investors looking for stable returns through dividends even during market fluctuations. Johnson & Johnson's (JNJ) stock rose by 0.05% as it reported beating analyst estimates for earnings and revenue in its latest quarterly earnings, prompting positive reactions from investors and analysts, with many raising their price targets for the stock. Johnson & Johnson (JNJ) stock recently rose by 0.05%, attributed to positive earnings exceeding forecasts, institutional investors increasing their positions, and favorable analyst ratings that suggest a "Moderate Buy" sentiment with elevated price targets.
	2025-02-12	-0.56 %
Johnson & Johnson's (JNJ) stock decreased by 0.56% to $155.27, despite a recent 7.24% gain over the past month, likely due to concerns about its long-term performance despite short-term gains. Johnson & Johnson (JNJ) stock experienced a decline of 0.56% due to a combination of market volatility in the biotechnology sector, uncertainties surrounding corporate acquisitions, and general economic factors following a recent drop in federal interest rates that did not generate the expected surge in investment activity. Johnson & Johnson (JNJ) stock recently declined by 0.56%, likely due to investor concerns reflected in the recent 13F filing by Tweedy Browne, which revealed a significant reduction in their holdings of JNJ as part of broader portfolio adjustments, suggesting a lack of confidence in its future performance.
	2025-02-11	+1.23 %
Johnson & Johnson (JNJ) stock rose by 1.23% last night due to strong financial results and growth prospects reported by Royalty Pharma plc, which highlighted a successful year in royalty receipts and a new $3 billion share repurchase program, reflecting confidence in their business and enhancing shareholder value.
	2025-02-07	-0.25 %
Johnson & Johnson (JNJ) stock recently fell by 0.25%, influenced by mixed analyst ratings, with some firms lowering their price targets, signaling potential concerns about the stock's future performance. Johnson & Johnson (JNJ) stock experienced a 0.25% decline, attributed to concerns over the financial implications of Omnicom's acquisition of IPG and the potential loss of significant clients, including JNJ, which raises doubts about IPG's future revenue and stability. Johnson & Johnson (JNJ) stock declined by 0.25% following a series of downgrades in target prices from several analysts, reflecting a cautious outlook for the company despite reporting better-than-expected earnings for the last quarter. Johnson & Johnson (JNJ) stock recently declined by 0.25%, influenced by a reduction in positions by major investors and analysts lowering their price targets for the stock. Johnson & Johnson (JNJ) stock experienced a decline of 0.25% following Optas LLC's disclosure of a 15.6% reduction in its holdings, amidst other institutional adjustments in stock positions. The stock decrease may reflect market sensitivity to hedge fund movements and changes in ownership structures, leading to investor uncertainty.
	2025-02-06	-0.76 %
Johnson & Johnson (JNJ) stock declined by 0.76% due to concerns that a stronger US dollar, influenced by President Trump's tariff plans, is negatively impacting the company's overseas revenue, as they reported a $1.7 billion adverse effect on 2024 sales from unfavorable foreign currency moves.
	2025-02-05	+0.78 %
Johnson & Johnson (JNJ) stock rose by 0.78% due to a mix of institutional investors adjusting their holdings positively and strong quarterly earnings results that exceeded analysts' expectations, indicating robust business performance. Johnson & Johnson (JNJ) stock rose 0.78% due to positive institutional investment activity, including increased stakes and recent insider purchases, along with strong quarterly earnings that surpassed expectations. Johnson & Johnson's stock (JNJ) rose by 0.78% after SeaBridge Investment Advisors LLC and other institutional investors increased their stakes in the company, reflecting growing investor confidence and a positive earnings report that exceeded analysts' expectations. Johnson & Johnson (JNJ) stock rose by 0.78% following reports of increased institutional investment and a positive quarterly earnings report, which included earnings surpassing expectations and revenue growth, coupled with a proposed dividend increase. Johnson & Johnson (JNJ) stock rose by 0.78% due to institutional investors increasing their stakes in the company, positive earnings reports exceeding analyst expectations, and recent upgrades from equity analysts.
	2025-02-04	+1.07 %
Johnson & Johnson (JNJ) stock rose by 1.07% partly due to positive quarterly earnings results, where the company reported higher-than-expected earnings and revenue, along with supportive actions from institutional investors and analysts raising price targets for the stock. Johnson & Johnson (JNJ) stock increased by 1.07% as institutional investors and hedge funds have significantly raised their stakes in the company, reflecting positive investor sentiment and confidence in its performance. Johnson & Johnson's (JNJ) stock rose by 1.07% likely due to significant institutional investment increases, positive quarterly earnings performance that exceeded expectations, and the announcement of a forthcoming dividend, all contributing to investor confidence in the company. Johnson & Johnson (JNJ) stock rose 1.07% due to positive institutional investor activities, strong quarterly earnings surpassing expectations, and an upcoming dividend payment, which collectively enhanced investor confidence. Johnson & Johnson (JNJ) stock rose by 1.07% due to positive investor sentiment, which could be influenced by strong institutional ownership and favorable analyst recommendations for its focus on innovative medical solutions.
	2025-02-03	-0.18 %
The article discusses the confirmation hearings for Robert F. Kennedy Jr. as HHS Secretary, highlighting the significant influence of the pharmaceutical industry on lawmakers, particularly those who criticize Kennedy while having received substantial donations from Big Pharma, which raises questions about their commitment to public health—this negative sentiment surrounding the hearings may contribute to the decline in Johnson & Johnson (JNJ) stock. Johnson & Johnson's stock may have gone down due to increased scrutiny and criticism of the pharmaceutical industry, potentially reflecting concerns about accountability, regulation, and public health priorities that can impact investor confidence. Johnson & Johnson (NYSE:JNJ) stock experienced a slight decline of -0.18%, attributed to increased competition and investment interest in oncology and AI stocks which are viewed as having greater growth potential than JNJ's current offerings.
	2025-01-31	-0.47 %
Johnson & Johnson (JNJ) stock declined by 0.47% due to a broader market trend influenced by perceptions shaped by specialty public relations, which significantly impact investor sentiment and market behavior. Johnson & Johnson (JNJ) stock fell by 0.47% due to broader market trends and investor concerns that may have overshadowed the company's performance. Johnson & Johnson's (JNJ) stock fell by 0.47% despite a recent upgrade in price target by Barclays due to concerns over large investor activity and mixed analyst ratings affecting market sentiment. The decline in JNJ's stock may be attributed to various factors including shifts in analyst price targets, a decrease in trading volume, and the overall market reaction to recent earnings results compared to previous performance.
	2025-01-30	+1.14 %
Johnson & Johnson (JNJ) stock rose by 1.14% due to a combination of positive quarterly earnings exceeding analyst expectations, modest increases in revenues, ongoing institutional investment activity, and favorable ratings from research analysts. Johnson & Johnson (JNJ) stock rose by 1.14% following positive quarterly earnings results that exceeded analyst expectations and the declaration of a quarterly dividend, indicating strong financial performance and ongoing confidence among investors. Johnson & Johnson (JNJ) stock rose by 1.14% following positive quarterly earnings results that exceeded consensus estimates, along with recommendations from analysts that boosted market confidence in the company's future performance. Johnson & Johnson's (NYSE: JNJ) stock rose 1.14% following an increase in its price target by Barclays from $159.00 to $166.00, coupled with positive quarterly earnings results that exceeded analyst expectations. The Johnson & Johnson (JNJ) stock rose 1.14% due to a positive earnings report that exceeded analysts' expectations, coupled with changes in institutional investors' holdings and an upgrade by some analysts to a "strong-buy" rating.
	2025-01-29	+0.51 %
Johnson & Johnson (JNJ) stock rose by 0.51% amid ongoing controversies involving pharmaceutical interests and the nomination of Robert F. Kennedy Jr. for a health position, which some perceive as a challenge to established Big Pharma policies and interests that may indirectly affect JNJ’s market performance.
	2025-01-28	-1.64 %
Johnson & Johnson (JNJ) stock fell 1.64% attributed to concerns over its drug discovery collaborations and the competitive landscape posed by innovative firms like Xtalpi, which is leveraging AI and quantum physics for faster and potentially more cost-effective drug development. The article reports that Johnson & Johnson (JNJ) stock fell by 1.64% following a purchase filed by Representative Marjorie Taylor Greene valued between $3,003 and $45,000. The decline in Johnson & Johnson's stock could be attributed to market reactions to the news of the purchase or broader market trends, but specific reasons for the decrease are not detailed in the provided text.
	2025-01-27	+4.13 %
Johnson & Johnson's stock (JNJ) rose 4.13% due to positive earnings results that exceeded estimates, a new stake purchase by MFA Wealth Services, and overall supportive activity from institutional investors in the fourth quarter. Johnson & Johnson (JNJ) stock rose 4.13% due to increased institutional investments and a positive earnings report, where it exceeded analysts' expectations for earnings per share and revenue growth. Johnson & Johnson (JNJ) stock increased by 4.13% following a strong earnings report that exceeded analysts' expectations, alongside significant investment activity from institutional investors and positive analyst ratings. Johnson & Johnson (JNJ) stock rose by 4.13% following an upgrade from a "buy" to a "strong-buy" rating by StockNews.com, along with positive reactions from various analysts and better-than-expected quarterly earnings results that exceeded analyst estimates. Johnson & Johnson's stock (JNJ) rose by 4.13% following positive quarterly earnings results that exceeded analyst expectations, along with continued strong institutional investment interest in the company.
	2025-01-24	+0.12 %
Johnson & Johnson (JNJ) stock rose 0.12% after the company reported better-than-expected Q4 results, with revenues of $22.5 billion and adjusted earnings of $2.04 per share, and provided an optimistic sales outlook for 2025, despite facing some challenges from biosimilar competition for one of its top-selling drugs.
	2025-01-23	+0.94 %
Johnson & Johnson's (JNJ) stock increased by 0.94% following unusual options trading activity and a positive quarterly earnings report that exceeded analysts' expectations, along with solid revenue growth year-over-year. Johnson & Johnson's stock (JNJ) increased by 0.94% following a quarterly earnings report that exceeded analysts' expectations, showcasing a revenue rise, which indicates strong performance and future growth potential despite some recent price target adjustments by analysts.
	2025-01-22	-1.94 %
Johnson & Johnson (JNJ) stock fell by 1.94% due to a combination of institutional investor movements, recent downgrades in target prices from several research analysts, and overall market conditions. Johnson & Johnson's stock (JNJ) fell by 1.94% following the FDA's approval of their nasal spray, Spravato, for treating major depressive disorder, which may have sparked concerns about competition in the market for depression treatments. Johnson & Johnson (JNJ) stock fell by 1.94%, influenced by recent analyst downgrades in price targets, reflecting a broader sentiment shift among investors, despite steady institutional investment growth and upcoming dividend announcements. Johnson & Johnson (JNJ) stock fell by 1.94% primarily due to analyst downgrades and shifts in institutional investor positions, as indicated by reduced ratings and targeted price cuts from various brokerages. Johnson & Johnson's (JNJ) stock fell by 1.94% despite positive fourth-quarter and full-year 2024 results due to concerns over ongoing legal issues related to talc products, potential negative impacts from foreign exchange and slower medical device sales, as well as competitive pressures from generics and pricing negotiations with Medicare.
	2025-01-21	+0.76 %
Johnson & Johnson (JNJ) stock rose by 0.76% following significant institutional investments, including a new position by Whitaker Myers Wealth Managers and increased stakes from several other hedge funds, along with positive analyst ratings and a commitment to a healthy dividend. Johnson & Johnson (JNJ) stock rose 0.76% ahead of its upcoming fourth-quarter earnings report, which is anticipated to show $2 in EPS and $22.44 billion in revenues, contributing to positive investor sentiment despite a 8.88% decline over the past year. The stock's rise may be attributed to expectations of positive earnings results and positive developments such as the approval of Spravato. Johnson & Johnson's stock increased by 0.76% as several institutional investors have recently adjusted their stakes in the company, alongside positive price target upgrades from various research firms, indicating strong market confidence in JNJ's long-term prospects. Johnson & Johnson (NYSE: JNJ) shares increased by 0.76% as institutional investors, including Smith Salley Wealth Management, made significant adjustments to their holdings, and positive analyst ratings lifted market sentiment. The stock's rise can be attributed to strong institutional buying activity and favorable analyst upgrades, indicating confidence in the company's financial performance and future growth prospects. Johnson & Johnson's stock rose 0.76% following the announcement of its merger agreement with Intra-Cellular Therapies, which involves acquiring the company for $132.00 per share in cash, reflecting investor optimism about potential growth and strategic benefits from the merger.
	2025-01-17	-0.5 %
Johnson & Johnson's stock (JNJ) dropped by 0.5% following a downgrade from a "strong-buy" rating to a "buy" rating by analysts at StockNews.com, despite positive earnings results that exceeded analysts' expectations. Johnson & Johnson (JNJ) stock, which was down 0.5%, is likely influenced by the broader market dynamics where a tech stock revival and positive earnings reports have shifted investor sentiment, while uncertainty surrounding upcoming policy changes under the Trump administration may have also contributed to JNJ's decline amid increased competition and regulatory pressures in the healthcare sector. Johnson & Johnson (JNJ) stock decreased by 0.5% amid a generally positive market environment where major indices surged after favorable CPI inflation data, which raised expectations for interest rate cuts by the Federal Reserve. The decline in JNJ's stock may be attributed to a broader focus on upcoming earnings reports and potential investor sentiment shifting towards other sectors that are performing well, particularly major banks. Johnson & Johnson (JNJ) stock fell by 0.5% due to ongoing concerns over lawsuits related to its talc products, alongside uncertainty surrounding broader market conditions influenced by upcoming political changes and earnings reports from other companies. Johnson & Johnson (JNJ) stock fell by 0.5% due to various market factors, including possible investor reaction to recent trades and broader market trends, although the article did not specifically elaborate on the reasons for the decline.
	2025-01-16	+1.93 %
The article discusses the ownership dynamics of NFL teams and the varying degrees of success associated with each owner, while highlighting that Johnson & Johnson (JNJ) stock rose by 1.93% last night, likely due to positive investor sentiment influenced by factors such as strong financial performance or strategic business developments.
	2025-01-15	+0.15 %
Johnson & Johnson (JNJ) stock rose by 0.15% due to strong institutional ownership and favorable analyst ratings, indicating market confidence in the company's long-term performance compared to competitors like RegeneRx Biopharmaceuticals. Johnson & Johnson (JNJ) stock rose by 0.15% due to a combination of analysts' positive target price adjustments and recent insider buying, alongside the company's strong quarterly earnings performance that exceeded expectations. Johnson & Johnson (JNJ) stock increased by 0.15% as part of a broader market trend where investors remain optimistic about healthcare stocks, despite mixed news surrounding competitors like Eli Lilly. The rise in JNJ stock may be attributed to positive sentiment in the healthcare sector and investors looking for stable investment opportunities.
	2025-01-14	+0.19 %
Johnson & Johnson (JNJ) stock rose 0.19% due to its acquisition of Intra-Cellular Therapies, Inc. for $132.00 per share in cash, which may have positively influenced investor sentiment regarding JNJ's growth prospects. Johnson & Johnson (JNJ) stock rose 0.19% last night, likely due to positive sentiments stemming from recent analyst upgrades and favorable performance indicators in the broader market context. Johnson & Johnson (JNJ) stock rose 0.19% recently, driven by increased investor confidence stemming from discussions of a potential $10 billion acquisition of Intra-Cellular Therapies Inc. (ITCI) following ITCI's successful sales of the antipsychotic drug Caplyta and its recent legal victory over Sandoz. Johnson & Johnson (JNJ) stock rose by 0.19% following the announcement that the company will acquire Intra-Cellular Therapies for $132 per share, which contributed to investor optimism in JNJ's future growth prospects. Johnson & Johnson (JNJ) stock rose 0.19% amid optimism surrounding recent acquisitions and potential regulatory changes under the new Trump administration, which may create a more favorable environment for the pharmaceutical industry compared to the uncertainty caused by the previous Inflation Reduction Act.
	2025-01-13	+1.7 %
Johnson & Johnson's stock (JNJ) rose by 1.7% after the company announced its acquisition of Intra-Cellular Therapies for approximately $14.6 billion, which includes the FDA-approved drug CAPLYTA® and a promising pipeline of treatments for neuropsychiatric disorders, positioning JNJ for significant sales growth in the coming years. Johnson & Johnson (JNJ) stock rose by 1.7% recently due to increased institutional investment, including a notable 6.5% increase in holdings by the Czech National Bank, alongside strong quarterly earnings that exceeded analysts' expectations. Johnson & Johnson's stock rose 1.7% following their announcement of a $14.6 billion acquisition of Intra-Cellular Therapies, which is expected to enhance their portfolio in treating central nervous system disorders. The increase in JNJ's stock is attributed to investor confidence in the growth potential of Intra-Cellular's drug Caplyta and its promising pipeline. Johnson & Johnson's stock rose 1.7% following the announcement of its acquisition of Intra-Cellular for over $14 billion, which aims to enhance its neurological drug division and expand into treating central nervous system disorders. Johnson & Johnson's stock rose 1.7% following its announcement to acquire Intra-Cellular Therapies for over $14 billion, which reflects a strategic move to enhance its portfolio in treating central nervous system disorders and capitalize on the growing market potential of Intra-Cellular's drug Caplyta.
	2025-01-10	-0.15 %
The article discusses Royalty Pharma plc's announcement of a transaction aimed at enhancing shareholder value, including a significant share repurchase program and internalization of management, while noting that Johnson & Johnson's stock (JNJ) declined by 0.15%. Johnson & Johnson's stock may have gone down due to general market trends or specific investor reactions to broader economic conditions impacting the biopharmaceutical sector, although the article does not provide detailed reasons for JNJ's decline. Johnson & Johnson (JNJ) stock fell by 0.15% amid underperformance in 2024 due to declining sales from Covid-19 vaccines and its drug Remicade, alongside increasing competition for key products. The article discusses a minor decline of 0.15% in Johnson & Johnson's stock, which can be attributed to broader market movements and recent insider trading activities rather than specific issues with the company's fundamentals. Johnson & Johnson's stock (JNJ) decreased by 0.15% following a downgrade in earnings per share estimates for Q2 2025 by Zacks Research, which raised concerns about the company's future financial performance. Johnson & Johnson (JNJ) stock experienced a 0.15% decline after Representative Lloyd Doggett's recent share purchase and a mixed response from analysts regarding future price targets and ratings, despite the company's reported earnings surpassing analyst expectations. The stock may be affected by ongoing market fluctuations and investor sentiment.
	2025-01-08	-2.71 %
Johnson & Johnson (JNJ) stock fell by 2.71% due to market uncertainties and negative investor sentiment surrounding its growth prospects and earnings outlook. Johnson & Johnson (JNJ) stock fell by 2.71% due to a general decline in healthcare stocks, as the broader market reacted to the Federal Reserve's recent meeting and signals suggesting a potential slowdown in rate easings, which impacted investor sentiment.
	2025-01-07	+1.79 %
Johnson & Johnson (JNJ) stock rose by 1.79% last night, which could be attributed to positive market sentiment or rumors regarding potential developments in the company, as the article primarily discusses leadership changes at XWELL, Inc. and does not provide specific details about JNJ's performance.
	2025-01-06	-0.37 %
The article discusses the stock performance of Johnson & Johnson (JNJ), which fell by 0.37%, highlighting that the company had lower revenue compared to its competitor Materialise, with analysts favoring the latter due to its stronger consensus rating and higher potential upside. JNJ stock may have declined due to negative market sentiment or concerns over its financial performance relative to other tech companies. Johnson & Johnson (NYSE: JNJ) stock declined by 0.37% due to an overall shift in investor focus towards high-quality dividend stocks, amidst concerns over valuation and demand in the AI sector. Johnson & Johnson (JNJ) stock declined by 0.37% as it faced downward pressure despite increased institutional holdings and analysts mostly maintaining positive outlooks, likely due to broader market trends or investor sentiment rather than company-specific issues. Johnson & Johnson (NYSE:JNJ) stock fell by 0.37% due to a notable reduction in its holdings by Burkett Financial Services LLC and fluctuations in investor sentiment, as several institutional investors made significant adjustments to their positions. Johnson & Johnson (JNJ) stock saw a decrease of 0.37% amid mixed analyst ratings and strategic investment movements by large institutional investors, with overall market sentiment likely influencing the decline.
	2025-01-03	+0.12 %
Johnson & Johnson (JNJ) stock rose by 0.12% due to recent FDA approvals of various drugs in regenerative medicine and treatments for rare diseases, which indicate a positive outlook for the healthcare sector and potentially beneficial developments for JNJ's market position. Johnson & Johnson (NYSE:JNJ) stock rose by 0.12% last night, largely influenced by increased institutional investment and favorable analyst ratings, including target price increases from several firms. Johnson & Johnson (JNJ) stock rose by 0.12% likely due to a mix of large investors adjusting their positions and positive analyst ratings, as well as strong quarterly earnings that surpassed expectations, highlighting the company's solid performance in the healthcare sector.
	2025-01-02	-0.41 %
Johnson & Johnson (JNJ) stock decreased by 0.41% primarily due to market reactions after analysts adjusted their price targets, reflecting mixed sentiments despite strong earnings and a consistent dividend history. Shares of Johnson & Johnson (JNJ) experienced a slight decline of 0.41% after trading activity showed significantly lower volume and despite positive analyst comments regarding its stock ratings and price targets. The decline in JNJ stock could be attributed to the overall trading environment and reduced investor interest, as indicated by the sharp drop in trading volume compared to its average. Johnson & Johnson (JNJ) stock recently declined by 0.41%, despite a decrease in short interest and positive analyst ratings, primarily due to market fluctuations and overall investor sentiment.
	2024-12-31	+0.89 %
Johnson & Johnson's stock (NYSE: JNJ) increased by 0.89% after Representative Marjorie Taylor Greene disclosed her recent purchase of shares, alongside positive earnings results that exceeded analysts' expectations, contributing to investor confidence. The stock's rise can be attributed to Greene's investment and strong quarterly earnings performance, which surpassed consensus estimates for both earnings per share and revenue. Johnson & Johnson (JNJ) stock rose by 0.89% due to positive sentiment surrounding biotechnology investments, particularly in Rallybio Co., which has recently received strong analyst ratings and institutional investments, suggesting a strong outlook in the sector.
	2024-12-30	-1.18 %
Johnson & Johnson's (JNJ) stock declined by 1.4% amid low trading volume, potentially influenced by mixed analyst ratings and a broader market environment. The stock's decline could be attributed to reduced investor confidence indicated by the significant drop in trading volume, combined with varying analyst opinions, despite the company’s positive earnings and revenue growth reported in its latest quarterly results. Johnson & Johnson (JNJ) stock declined by 1.18% due to market fluctuations and possibly investor reactions to recent institutional buying activity, as evidenced by varying positions taken by multiple institutional investors and analysts adjusting their price targets and ratings.
	2024-12-27	-0.36 %
Johnson & Johnson (JNJ) stock declined by 0.36% as it entered a bearish technical pattern known as the Death Cross, indicating potential further declines due to the 50-day moving average dropping below the 200-day moving average. Johnson & Johnson (JNJ) stock declined by 0.36% due to ongoing concerns related to its settlement offer aimed at resolving thousands of lawsuits over its talcum powder products linked to ovarian cancer, as the company moved to finalize a $9 billion settlement through a pre-packaged bankruptcy process for its Red River Talc unit.
	2024-12-23	+0.55 %
Johnson & Johnson (JNJ) stock rose by 0.55% due to positive market sentiment and an overall sense of normalcy returning to the economy, despite the company's recent financial reporting issues and fines related to price hikes on their products.
	2024-12-20	+0.62 %
Johnson & Johnson (JNJ) stock rose by 0.62% due to the positive sentiment surrounding Clearside Biomedical, which received multiple "buy" ratings from analysts, indicating strong market confidence in the company's future performance.
	2024-12-17	+1.78 %
Johnson & Johnson (JNJ) stock rose 1.78%, likely as a result of its relative stability amidst significant declines in the health insurance sector, particularly due to the recent turmoil surrounding UnitedHealth Group, which has caused a broader negative sentiment in the market. Johnson & Johnson (JNJ) stock rose by 1.78% despite the Dow Jones Industrial Average experiencing its worst losing streak in nearly 50 years, mainly due to a broader sell-off in healthcare stocks impacting the Dow, but JNJ managed to rebound while other stocks struggled. JNJ's stock may have gone up as it benefited from some investors seeking value amidst the overall decline in the healthcare sector, indicating a potentially positive sentiment or correction following previous losses. Johnson & Johnson (JNJ) stock rose 1.8% amid a generally declining market due to strong performance and forecasts from other healthcare companies, particularly Pfizer, which helped buoy investor confidence in the sector.
	2024-12-16	-1.89 %
Johnson & Johnson (JNJ) stock dropped by 1.89% due to market reactions surrounding significant industry news, specifically Omnicom's proposed $30 billion acquisition of Interpublic Group, which has raised concerns about potential disruptions and uncertainties among clients and shareholders within the advertising sector.
	2024-12-09	+0.19 %
Johnson & Johnson (JNJ) stock rose 0.19% last night, likely benefiting from its strong position in the Drucker Institute's Management Top 250 ranking, where it was recognized as the sixth best-run company in America, alongside other high-performing companies that emphasize corporate effectiveness.
	2024-12-06	-0.14 %
Johnson & Johnson (JNJ) stock fell by 0.14% mainly due to its recent oversold condition, indicated by an RSI of 29.0, suggesting heavy selling pressure that may present a buying opportunity for dividend investors. Johnson & Johnson (JNJ) stock was down by 0.14% likely due to market fluctuations, investor sentiment, or external economic factors affecting healthcare stocks, as the article primarily discusses Rallybio's ratings and performance rather than focusing on JNJ directly.
	2024-12-05	-0.63 %
Johnson & Johnson (JNJ) stock experienced a decline of 0.63% due to overall market volatility and likely investor sentiment weighing on the healthcare sector despite the company's strong fundamentals and innovative growth strategies.
	2024-12-03	-1.58 %
Johnson & Johnson (JNJ) stock was down 1.58% last night, likely due to broader market trends, investor sentiment shifts, or company-specific news impacting its share price, although the article primarily discusses Clearside Biomedical, Inc. and does not directly provide reasons for JNJ's decline.
	2024-12-02	-0.14 %
The article discusses a comparison between two small-cap technology companies, Materialise and MeridianLink, while noting that Johnson & Johnson (JNJ) stock decreased by 0.14% last night, although it does not provide specific reasons for this decline. The drop in Johnson & Johnson's stock price could be due to a variety of factors, such as broader market trends, company-specific news, or investor sentiment, but the article does not specify the cause. Johnson & Johnson (JNJ) stock fell by 0.14% after Dynamic Technology Lab Private Ltd drastically reduced its holdings in the company by 79.5%, impacting market sentiment.
	2024-11-29	-0.25 %
Johnson & Johnson (JNJ) stock declined by 0.25%, likely due to market reactions to the impending end of the lock-up period for Rapport Therapeutics, which may lead to increased selling pressure from insiders and institutional investors.
	2024-11-27	+0.57 %
Johnson & Johnson (JNJ) stock increased by 0.57% due to its strong revenue growth in both pharmaceuticals and medical devices, driven by successful drugs like Darzalex and Stelara, despite facing challenges with older drugs and upcoming loss of exclusivity for Stelara.
	2024-11-22	-0.21 %
The article discusses recent performance insights of Johnson & Johnson (JNJ) stock, which dropped by 0.21%, but primarily focuses on Clearside Biomedical (CLSD), which received a "Buy" rating from analysts and saw significant insider investment. The decline in JNJ stock might be linked to broader market conditions or specific company news, although the article does not provide direct reasons for the drop. Johnson & Johnson (JNJ) stock fell by 0.21% amidst concerns related to a UK class action lawsuit alleging that nearly 2,000 women claim the company's talcum powder products contained asbestos, potentially causing cancer. The stock decline is attributed to the resurgence of legal actions and public scrutiny surrounding the safety of J&J's talc-based products following claims that they may have contained asbestos fibres linked to serious health risks, such as incurable cancer.
	2024-11-21	+1.56 %
Johnson & Johnson (JNJ) stock rose by 1.56% last night, driven by strong revenue growth in its pharmaceuticals and medical devices segments, particularly from treatments for multiple myeloma and autoimmune diseases, despite facing challenges from older drugs losing market exclusivity. Johnson & Johnson (JNJ) stock rose 1.56% last night, likely due to positive investor sentiment and expectations of robust performance in the healthcare sector as potential policy shifts under the Trump administration may favor merger and acquisition activity. Additionally, the article highlights Howard Lutnick, the CEO of Cantor Fitzgerald, who has been nominated by Trump to be commerce secretary, and examines his controversial reputation on Wall Street amid discussions of potential conflicts of interest in his financial dealings.
	2024-11-20	+0.07 %
Johnson & Johnson (JNJ) stock rose by 0.07% likely due to investor confidence influenced by Dr. Mehmet Oz's nomination to lead the Centers for Medicare & Medicaid Services, as his significant investments in healthcare companies, including JNJ, could foster favorable decisions for the healthcare sector.
	2024-11-19	-1.14 %
Johnson & Johnson (JNJ) stock fell by 1.14%, likely due to broader market trends or specific company-related factors that impacted investor sentiment. The article discusses the recent downturn of Johnson & Johnson (JNJ) stock, which fell by 1.14%, but does not provide specific reasons for this decline as it mainly focuses on Clearside Biomedical's stock performance and ratings. Johnson & Johnson (JNJ) stock fell by 1.14% following mixed analyst ratings and changes in price targets amid concerns about its recent earnings performance and market dynamics.
	2024-11-18	+0.5 %
Johnson & Johnson (JNJ) stock increased by 0.5% likely due to positive developments in the myopia treatment sector, particularly following the FDA approval of its ACUVUE Ability Overnight Therapeutic Lenses, contrasting with the failure of Eyenovia's CHAPERONE study that negatively impacted its competitor's stock. The article discusses recent activity and analyst ratings for Clearside Biomedical (CLSD), noting that Johnson & Johnson (JNJ) has invested in the company, which may have contributed to a positive sentiment around its stock performance. The stock price increases are attributed to positive earnings reports exceeding analysts' expectations and increased insider buy-ins, indicating optimism about the company's future.
	2024-11-14	-0.89 %
The article discusses a viral Reddit post featuring a boy's unconventional use of duct tape, which has sparked both amusement and disbelief among users. Johnson & Johnson's (JNJ) stock fell by 0.89% possibly due to broader market trends, company-specific news, or concerns among investors, but the article does not provide specific details on the reasons for the decline.
	2024-11-13	+0.39 %
The article discusses the recent rise in Johnson & Johnson's (JNJ) stock, which was reported to be up by 0.39%, and highlights the positive ratings and institutional investment in Rallybio Co. (RLYB), without directly explaining JNJ's stock increase. The increase in JNJ's stock may be attributed to strong institutional buying and the company's continued investment in biotechnology projects, indicating confidence in future growth potential. Johnson & Johnson (JNJ) stock rose by 0.39% recently, likely due to positive investor sentiment and continued interest in its strong long-term growth potential, as demonstrated by its inclusion in significant investment portfolios like ETFs and its historical portfolio performance.

1
500 / page